Stereotactic radiotherapy for prostate cancer: A review and future directions

Table 3 Summary of gastrointestinal toxicities for included stereotactic body radiotherapy prostate trials

Study	Acute			Late			Clinical notes
	Gr. 1	Gr. 2	Gr. ≥ 3	Gr. 1	Gr. 2	Gr. ≥ 3
Madsen (IJROBP, 2007)	26%	13%	0%	30%	7.50%	0%	Gr. 2 events were proctitis
Pham (IJROBP, 2010)				22.50%	7.50%	0.00%	All toxicities resolved
Boike (JCO, 2011)1	33%	22.50%	0%	22.20%	2 tot	1 tot	Gr. 4 event due to rectal ulcer
Katz (BMC Urol, 2010)1	74.90%	3.60%	0%	5.10%	2.30%	0%
Jabarri (IJROBP, 2012)	21%	11%	0%	2 tot	1 tot	0%
King (IJROBP, 2012)1	Not reported	Not reported	Not reported	14.00%	1 tot	0%
McBride (Cancer, 2012)	31%	7%	0%	7%	7%	2 tot	Gr. 3 events were proctitis requiring ablation
Anwar (Rad Oncol, 2016)	42%	10%	0%	12.50%	0%	0%
Mantz (Fontiers Rad Oncol, 2014)	0%	0%	0%	3 tot	0%	0%	Toxicity was rectal bleeding
Hannan (Eur J Cancer, 2016)1	37.40%	20.90%	2 tot	25.30%	13.20%	6.60%	1 acute and 2 late Gr. 4 events (one rectal bleed)
Freeman (Rad Oncol, 2011)	Not reported	Not reported	Not reported	13%	1 tot	0%
Davis (Cureus, 2015)	4%/1%/1%2	1%/0%/0%2	0%	4%/3%/3%2	0%	0%

¹Aggregate values for all cohorts;

²Notation as follows: Diarrhea/constipation/proctitis.